{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:11:03Z","timestamp":1789186263234,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.06.029","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:36:43Z","timestamp":1785296203000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-8738","authenticated-orcid":false,"given":"Wolfgang A.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6229-9239","authenticated-orcid":false,"given":"Arathi R.","family":"Setty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-2833","authenticated-orcid":false,"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-5824","authenticated-orcid":false,"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-2051","authenticated-orcid":false,"given":"Lisa","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avani D.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Zerad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Kadakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lagunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-1780","authenticated-orcid":false,"given":"Daniel","family":"Blockmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-7345","authenticated-orcid":false,"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ard.2026.06.029_bib0001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/03009742.2014.982701","article-title":"The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950\u20132009","volume":"44","author":"Chandran","year":"2015","journal-title":"Scand J Rheumatol."},{"issue":"10","key":"10.1016\/j.ard.2026.06.029_bib0002","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaophthalmol.2019.2919","article-title":"Association of giant cell arteritis with race","volume":"137","author":"Gruener","year":"2019","journal-title":"JAMA Ophthalmol."},{"issue":"10","key":"10.1016\/j.ard.2026.06.029_bib0003","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol."},{"issue":"7","key":"10.1016\/j.ard.2026.06.029_bib0004","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/jcm11071799","article-title":"Treatment of Giant Cell Arteritis (GCA)","volume":"11","author":"R\u00e9gent","year":"2022","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.ard.2026.06.029_bib0005","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2021-220347","article-title":"Treatment failure in giant cell arteritis","volume":"80","author":"Unizony","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.06.029_bib0006","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","article-title":"Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK","volume":"5","author":"Gale","year":"2018","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.ard.2026.06.029_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.06.009","article-title":"2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis","author":"Mukhtyar","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2026.06.029_bib0008","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.ard.2026.06.029_bib0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","article-title":"British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis","volume":"59","author":"Mackie","year":"2020","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"10.1016\/j.ard.2026.06.029_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.ard.2026.06.029_bib0011","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3899\/jrheum.2022-1214","article-title":"Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: a single-enterprise cohort study","volume":"50","author":"Samec","year":"2023","journal-title":"J Rheumatol."},{"issue":"20","key":"10.1016\/j.ard.2026.06.029_bib0014","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ard.2026.06.029_bib0012","series-title":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis","year":"2025"},{"key":"10.1016\/j.ard.2026.06.029_bib0013","series-title":"RINVOQ\u00ae (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)","year":"2025"},{"issue":"2","key":"10.1016\/j.ard.2026.06.029_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.ard.2026.06.029_bib0016","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ard.2026.06.029_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes."},{"issue":"10","key":"10.1016\/j.ard.2026.06.029_bib0018","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res."},{"issue":"10","key":"10.1016\/j.ard.2026.06.029_bib0019","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1007\/s12325-025-03328-y","article-title":"Safety profile of upadacitinib: descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease","volume":"42","author":"Burmester","year":"2025","journal-title":"Adv Ther."},{"issue":"4","key":"10.1016\/j.ard.2026.06.029_bib0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-019-00180-9","article-title":"Risk of potential glucocorticoid-related adverse events in patients with giant cell arteritis: results from a USA-based electronic health records database","volume":"6","author":"Best","year":"2019","journal-title":"Rheumatol Ther."},{"issue":"5","key":"10.1016\/j.ard.2026.06.029_bib0021","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40744-025-00778-2","article-title":"Real-world analysis of patient characteristics, adverse events, and economic burden among patients with giant cell arteritis treated with glucocorticoids","volume":"12","author":"Curtis","year":"2025","journal-title":"Rheumatol Ther."},{"issue":"1","key":"10.1016\/j.ard.2026.06.029_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci."},{"issue":"10","key":"10.1016\/j.ard.2026.06.029_bib0024","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1093\/rheumatology\/keab076","article-title":"Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure","volume":"60","author":"Robson","year":"2021","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.029_bib0025","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000928","article-title":"Is giant cell arteritis associated with increased risk of cardiovascular disease? A meta-analysis","author":"Jain","year":"2025","journal-title":"Cardiol Rev."},{"issue":"4","key":"10.1016\/j.ard.2026.06.029_bib0026","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/jcm11041005","article-title":"An updated review of cardiovascular events in giant cell arteritis","volume":"11","author":"de Boysson","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ard.2026.06.029_bib0027","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/keab507","article-title":"All-cause and cause-specific mortality in patients with giant cell arteritis: a nationwide, population-based cohort study","volume":"61","author":"Therkildsen","year":"2022","journal-title":"Rheumatology (Oxford)."},{"issue":"5","key":"10.1016\/j.ard.2026.06.029_bib0028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/joim.13446","article-title":"Risk of venous and arterial thromboembolism in patients with giant cell arteritis and\/or polymyalgia rheumatica: a veterans health administration population-based study in the United States","volume":"291","author":"Michailidou","year":"2022","journal-title":"J Intern Med."},{"issue":"1","key":"10.1016\/j.ard.2026.06.029_bib0029","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/rheumatology\/kez251","article-title":"Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data","volume":"59","author":"Mahr","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.029_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol."},{"issue":"3","key":"10.1016\/j.ard.2026.06.029_bib0031","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged >\/=19 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"1","key":"10.1016\/j.ard.2026.06.029_bib0032","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/diagnostics12010182","article-title":"High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or Jak inhibitors: a clinical and ultrasonographic study","volume":"12","author":"Frade-Sosa","year":"2022","journal-title":"Diagnostics (Basel)."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:04:27Z","timestamp":1789185867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726004140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S0003496726004140"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.029","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AbbVie Inc. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}